 |
Indication & Dosage |
| |
| |
| Oral |
| SPASTICITY ASSOCIATED WITH MULTIPLE SCLEROSIS OR WITH SPINAL CORD INJURY OR DISEASE |
| Adult:
18 yr: Initially, 2 mg once daily increased according to response by 2-mg increments at intervals of at least 3-4 days up to 24 mg daily in 3-4 divided doses. Max: 8 mg/dose. Max: 24 mg/day.
Elderly: Not recommended. |
| |
| Oral |
| PAINFUL MUSCLE SPASM ASSOCIATED WITH MUSCULOSKELETAL CONDITIONS. |
| Adult:
>18 yr: 2-4 mg tid.
Elderly: Not recommended. |
|
| |
|
| Precautions |
Hepatic or renal insufficiency. Children, elderly, pregnancy and lactation. Monitor LFT regularly. Stop treatment if liver enzymes are raised persistently >3 times upper limit of normal range. Avoid abrupt withdrawal of therapy. |
| |
|
Potentially Life-threatening
Adverse Drug Reactions |
Drowsiness, fatigue, dizziness, insomnia, headache, anxiety, nausea, dryness of mouth, GI disturbances, hypotension, bradycardia, muscle pain and weakness, transient increase in serum transaminases, hallucinations. |
| |
|
| Adverse Drug Reactions |
Hepatitis. |
| |
|
| Interactions |
Potentiates hypotensive effect of antihypertensives. Increased CNS effects with alcohol and CNS depressants. Increased bradycardia with β-blockers and digoxin. Increased serum concentration of tizanidine with CYP1A2 inhibitors e.g. zileuton, ciprofloxacin and other fluoroquinolones, antiarrhythmics, cimetidine, famotidine, oral contraceptives, aciclovir and ticlopidine. Decreased serum concentrations of tizanidine with rifampicin. Use with caution with drugs that may prolong QT interval. |
| |
|
|
|
